Efficacy and Safety of Bevacizumab Plus Erlotinib for Patients with Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: A Trial of the Chicago, PMH, and California Phase II Consortia

OBJECTIVES: The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer. METHODS: This was a single arm, multicenter phase II trial with overall obje...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Friberg, Gregory, Kasza, Kristen, Faoro, Leonardo, Salgia, Ravi, Stadler, Walter M., Vokes, Everett E., Fleming, Gini F.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2699608/
https://ncbi.nlm.nih.gov/pubmed/18423560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2008.02.009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars